je.st
news
Home
› La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
2014-09-03 11:49:25| drugdiscoveryonline Home Page
La Jolla Pharmaceutical Company a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, recently announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure
Tags: company
trial
patient
clinical
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||